SHOP APOTHEKE EUROPE N.V.: Annual General Meeting welcomes European growth strategy.

^{NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.}

SHOP APOTHEKE EUROPE N.V.: Annual General Meeting welcomes European growth strategy.
 

• Review of the successful financial year 2017.
• Agenda items approved by large majorities.

Venlo, 26 April 2018. Today's Annual General Meeting of SHOP APOTHEKE EUROPE N.V. promoted the growth course of Europe's leading online pharmacy. A total of 58.66% of the share capital was represented. This corresponds to 7,051,450 shares. As part of their presentation, the members of the Management Board reviewed the financial year 2017 and gave a positive outlook for the financial year 2018 to the shareholders. The Annual General Meeting approved the agenda items proposed by the management with large majorities.

Michael Köhler, CEO of SHOP APOTHEKE EUROPE N.V., comments: "The strong support by our shareholders is a valid confirmation of our success story, both operationally and strategically".

After a compelling first quarter 2018, in which the Group more than doubled its sales volume compared to the same period last year, the Management Board has reaffirmed its ambitious growth targets for the current year. "We are targeting a further substantial revenue increase in 2018 and at the same time pursue our profitable growth guidance", CFO Dr. Ulrich Wandel adds.

For the full year 2018, SHOP APOTHEKE EUROPE is budgeting an increase in group revenues of 87% to 97% to EUR 530 m to 560 m as well as a positive EBITDA (before one-off costs) at group level of EUR 0 to 2 m.

Further information about the Annual General Meeting can be found in the Investor Relations section of the company's website www.shop-apotheke-europe.com.
 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in Continental Europe. SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leading. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to about 2.8 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services. SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.

MEDIA CONTACTS.

Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: presse@shop-apotheke.com

Investor Relations:
Dr. Ulrich Wandel
Telephone: +31 77 850 6117
Email: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This publication is an advertisement.
This communication constitutes neither an offer to sell nor a solicitation to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is not a securities prospectus. No public offering of any securities of Shop Apotheke Europe N.V. is being made.

Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.